Skip to main content
NIHR Barts Biomedical Research Centre
  1. NIHR Barts Biomedical Research Centre
  2. News and Events
  3. Items

Update from the Principal: Professor Sir Mark Caulfield appointed Vice-Principal (Health)

Principal Professor Colin Bailey has written to all staff announcing the appointment of Professor Sir Mark Caulfield as the new Vice-Principal (Health).

Published:
Prof Sir Mark Caulfield

Professor Sir Mark Caulfield.

Dear colleague,

I am delighted to announce that, following an extensive international search, we have appointed Professor Sir Mark Caulfield as our new Vice-Principal (Health).

Many of you will already know Mark. He trained at our historic institutions the London Hospital Medical College and Barts, joining Queen Mary in 1995 following the merger as a clinician scientist and is Professor of Clinical Pharmacology in our William Harvey Research Institute. He is currently CEO of Barts Life Sciences, a research and innovation partnership between Queen Mary University of London and Barts Health NHS Trust.

Mark brings an outstanding research pedigree and a huge amount of strategic leadership experience to the role. With his team and international collaborators he has discovered over 1,300 gene regions affecting blood pressure and conducted clinical studies with global impact on the treatment of high blood pressure. As Chief Scientist for Genomics England he led the scientific strategy and delivery of the 100,000 genomes project and co-created a new NHS Genomic Medicine Service which has delivered life-changing results for many patients and offers equity of access to genomics across England. He was Director and then Co-Director of the William Harvey Research Institute between 2003 and 2020. He was elected to the Academy of Medical Sciences in 2008 was knighted for services to the 100,000 Genomes Project in 2019 and joined Barts Health Board as a non-Executive Director. A short biography of Mark can be found on our website.

Mark takes over from Professor Irene Leigh from the 1st of January. I am sure you will join with me in heartfelt thanks to Irene for her outstanding and influential interim leadership of the faculty, and congratulations to Mark. In due course we will be commencing an international search for a successor to Mark as CEO of Barts Life Sciences.

Best wishes,

Colin

 

 

Back to top